As dengue surges globally, an Indian vaccine candidate has entered the final stage of testing, raising hopes for one of the world’s first single-dose shots against the deadly mosquito-borne disease.
Dengue, which causes severe flu-like symptoms and debilitating body aches, has exploded globally, fueled by rising temperatures and densely populated cities.
The WHO said that almost half of the world’s population is now at risk, with 100 million to 400 million infections every year. India alone has recorded more than 1 million cases and at least 1,500 deaths since 2021.
Photo: AFP
Hoping to stem the global epidemic, Panacea Biotec has begun the final and third phase of trials for its vaccine, DengiAll, which it has been pursuing for nearly 15 years. More than 10,000 volunteers across the country are enrolled in the study, overseen by the Indian Council of Medical Research, with the vaccine on track for rollout as early as next year if the trial results are favorable.
“We will try to get this vaccine out there as soon as possible,” Panacea chief scientific officer Syed Khalid Ali said.
Monsoon outbreaks regularly push Indian hospitals to their limits, crowding urban wards and leaving rural regions grappling with late diagnoses and poor access to care.
Higher temperatures and changing rainfall patterns create ideal conditions for Aedes mosquitoes — the vectors of dengue — to reproduce and spread the virus.
Children are particularly vulnerable to the more severe form, called dengue hemorrhagic fever, as they are more likely to suffer low platelet counts and shock.
Participants in the phase three trials, which started in 2024, were randomly assigned to receive either the vaccine or a placebo, with the results expected later this year.
Vaccines against all four dengue serotypes have long posed a scientific challenge. Immunity to one strain does not protect against others, and secondary infections could be more severe. Most existing candidates require multiple doses.
If approved, DengiAll would become one of the world’s first single-dose dengue vaccines, following Brazil’s approval of a similar shot last year. It would also be the first such vaccine available in India, where no dengue shot is licensed for public use.
Inside the Panacea’s research labs, doctor Priyanka Priyadarsiny, head of biological research and development, said vaccine development involves several steps, from proof-of-concept studies to regulatory checks.
“We are extremely cautious about purity, safety and adverse effects,” she said. “Only after meeting regulatory specifications can a product be considered safe for public use.”
The WHO recommends only one dengue vaccine, Qdenga, produced by Japan’s Takeda for children aged six to 16 in high-transmission settings. Qdenga, which requires two doses administered three months apart, is not available in India.
Ali said DengiAll could be given to people aged one to 60 and is expected to offer long-term protection.
In India, final approval would come from the Drugs Controller General of India, while WHO prequalification would be required for large-scale international use.
Experts said a successful Indian vaccine could be key to affordability and mass rollout in lower-income countries.
Virologist and Oxford University fellow Shahid Jameel — who is not connected with the trial — warned that dengue incidence could rise by 50 percent to 75 percent by 2050 given climate change trends.
Still, he cautioned that only phase three results would determine whether a candidate meets the criteria for a safe and effective dengue vaccine.
“Phase III testing and follow-up are needed to show if the above conditions are met,” he said. “Only then can we have a useful dengue vaccine. It is still early days, but there is hope for the future.”
ROCKY RELATIONS: The figures on residents come as Chinese tourist numbers drop following Beijing’s warnings to avoid traveling to Japan The number of Chinese residents in Japan has continued to rise, even as ties between the two countries have become increasingly fractious, data released on Friday showed. As of the end of December last year, the number of Chinese residents had increased by 6.5 percent from the previous year to 930,428. Chinese people accounted for 22.6 percent of all foreign residents in Japan, making them by far the largest group, Japanese Ministry of Justice data showed. Beijing has criticized Tokyo in increasingly strident terms since Japanese Prime Minister Sanae Takaichi last year suggested that a military conflict around Taiwan could
A retired US colonel behind a privately financed rocket launch site in the Dominican Republic sees the project as a response to China’s dominance of the space race in Latin America. Florida-based Launch on Demand is slated to begin building a US$600 million facility in a remote region near the border with Haiti late this year. The project is designed to meet surging demand for the heavy-lift rockets needed to put clusters of satellites into orbit. It is also an answer to China’s growing presence in the region, said CEO Burton Catledge, a former commander of the US Air Force’s 45th Operations
Germany is considering Australia’s Ghost Bat robot fighter as it looks to select a combat drone to modernize its air force, German Minister of Defense Boris Pistorius said yesterday. Germany has said it wants to field hundreds of uncrewed fighter jets by 2029, and would make a decision soon as it considers a range of German, European and US projects developing so-called “collaborative combat aircraft.” Australia has said it will integrate the Ghost Bat, jointly developed by Boeing Australia and the Royal Australian Air Force, into its military after a successful weapons test last year. After inspecting the Ghost Bat in Queensland yesterday,
A pro-Iran hacking group claimed to breach FBI Director Kash Patel’s personal e-mail inbox and posted some of the contents online. The e-mails provided by the hacking group include travel details, correspondence with leasing agents in Washington and global entry, and loyalty account numbers. The e-mail address the hackers claim to have compromised has been previously tied to Patel’s personal details, and the leaked e-mails contain photos of Patel and others, in addition to correspondence with family members and colleagues. “The FBI is aware of malicious actors targeting Director Patel’s personal email information,” the agency said in a statement on
RSS